Skip to main content
SpringerLink
Log in

Hemodynamic effects of the novel cardiotonic drug simendan: Echocardiographic assessment in healthy volunteers

  • Positive Inotropic Agents
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Simendan is a novel cardiotonic drug with mixed properties, including calcium sensitization. Simendan was given intravenously to eight healthy volunteers in doses from 0.1 to 10.0 mg to define its safety and dose-response effects. Its effects on myocardial function were recorded by echocardiography with simultaneous measurement of heart rate (HR) and blood pressure (BP). A linear dose response was observed in all echocardiographic indices. Fractional shortening increased from a basal value of 29.5% to 32.4% (p<0.05), 34.7% (p<0.001), and 39.4% (p<0.001) 10 minutes after doses of 1.0, 2.0, and 5.0 mg of simendan, respectively. The mean velocity of maximal circumferential fiber shortening increased from the baseline of 2.22 lengths/sec to 2.7 lengths/sec after the 2.0 mg dose (p<0.05) and to 3.31 lengths/sec after the 5.0 mg dose (p<0.001). Mean BP decreased slightly and mean HR increased only by 5.2 beats/min after the 5.0 mg dose. Because of the potent effect seen on hemodynamic indices and due to two vasovagal reactions, 10 mg was given to two subjects only. These results revealed that simendan has hemodynamic effects that can be explained by positive inotropy as well as vasodilatation, in agreement with preclinical findings. Further studies with patients disabled by heart failure are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferrick KJ, Fein SA, Ferrick AM, Doyle JT. Effect of milrinone on ventricular arrhythmias in congestive heart failure.Am J Cardiol 1990:66:431–434.

    PubMed  Google Scholar 

  2. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.N Engl J Med 1989;320:677–683.

    PubMed  Google Scholar 

  3. Borow KM, Come PC, Neumann A, Baim DS, Braunwald E, Grossman W. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease.Am J Cardiol 1985;55:1204–1209.

    PubMed  Google Scholar 

  4. Böhm M, Beuckelmann D, Brown L, et al. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium.Eur Heart J 1988;9:844–852.

    PubMed  Google Scholar 

  5. Miller WP, Vander Ark CR, Wiederholt P. Effect of oral milrinone on end-systolic relations in patients with severe congestive heart failure.Am J Cardiol 1987;60:842–846.

    PubMed  Google Scholar 

  6. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.N Engl J Med 1982;307:205–211.

    PubMed  Google Scholar 

  7. Bobik A, Little PJ. Role of cyclic AMP in cardiac beta-adrenoceptor desensitization: Studies using prenalterol and inhibitors of phosphodiesterase.J Cardiovasc Pharmacol 1984;6:795–801.

    PubMed  Google Scholar 

  8. Ovaska M, Haikala H, Lundström K, Korkolainen T, Taskinen J, Linden I-B. Studies on calcium-dependent binding of simendan to troponin complex and troponin C.J Mol Cell Cardiol 1992;24(Suppl I):S260.

    Google Scholar 

  9. Haikala H, Linden I-B, Pohto P. Simendan, a novel calcium sensitizer, is as potent and efficient in the skinned fibre as in the electrically paced papillary muscle.J Mol Cell Cardiol 1992;24(Suppl I):S260.

    Google Scholar 

  10. Edes I, Papp J, Csanady M. A unique effect of the new positive drug simendan (OR-1259) on the phosphorylation of key intracellular proteins (abstr).Eur Heart J 1992;13:167.

    Google Scholar 

  11. Edes I, Papp J, Csanady M. The effects of a new calcium sensitizer, simendan, on intracellular protein phosphorylation (abstr).J Mol Cell Cardiol 1991;24(Suppl V):S93.

    Google Scholar 

  12. Raasmaja A, Talo A, Nissinen E, Linden I-B, Pohto P. Biochemical mechanisms of the novel cardiotonic agent OR-1259.J Mol Cell Cardiol 1991;23(Suppl V):S129.

    Google Scholar 

  13. Haikala H, Levijoki J, Leino T, Linden I-B, Pohto P. Antiarrhythmic effect and altered calcium sequestration by a cardiotonic agent OR-1259.J Mol Cell Cardiol 1991;23(Suppl V):S129.

    Google Scholar 

  14. Vegh A, Udvary E, Papp J. Effects of simendan in a model of acute heart failure produced by severe regional ischaemia in dogs.J Mol Cell Cardiol 1992;24(Suppl V):S45.

    Google Scholar 

  15. Upton MT, Gibson DG. The study of the left ventricular function from digitized echocardiograms.Prog Cardiovasc Dis 1978;20:359–384.

    PubMed  Google Scholar 

  16. Roelandt J, Gibson DG. Recommendations for standardization of measurements from digitized echocardiograms.Eur Heart J 1980;1:375–378.

    PubMed  Google Scholar 

  17. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergy.Am J Cardiol 1976;37:7–11.

    PubMed  Google Scholar 

  18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement.Lancet 1986;1:307–310.

    PubMed  Google Scholar 

  19. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergy.Am J Cardiol 1976;37:7–11.

    PubMed  Google Scholar 

  20. Kupari M. Reproducibility of M-mode echocardiographic assessment of left ventricular function. Significance of the temporal range of measurements.Eur Heart J 1984;5:412–418.

    PubMed  Google Scholar 

  21. Groundstroem KW, Huikuri HV, Ikäheimo MJ, Korhonen UR, Linnaluoto MK, Takkunen JT. Echocardiographic assessment of left ventricular function during isometric exercise in aortic valve incompetence.Am J Noninvas Cardiol 1989;3:342–347.

    Google Scholar 

  22. Quinones MA, Gaasch WH, Cole JS, Alexander JK. Echocardiographic determination of left ventricular stressvelocity relations in man: With reference to the effects of loading and contractility.Circulation 1975;51:689–700.

    PubMed  Google Scholar 

  23. Quinones MA, Gaasch WH, Alexander JK. Influence of acute changes in preload, afterload, contractile state and isovolumic indices of myocardial contractility in man.Circulation 1976;53:293–302.

    PubMed  Google Scholar 

  24. DeMaria AN, Neumann A, Schubart PJ, Lee G, Mason DT. Systematic correlation of cardiac chamber size and ventricular performance determined with echocardiography and alterations in heart rate in normal persons.Am J Cardiol 1979;43:1–9.

    PubMed  Google Scholar 

  25. Erbel R, Schweizer P, Krebs W, Langen H-L, Meyer J, Effert S: Effects of heart rate changes on left ventricular volume and ejection fraction: A 2-dimensional echocardiographic study.Am J Cardiol 1984;53:590–597.

    PubMed  Google Scholar 

  26. Ross BA, Hughes S, Anderson E, Gillette PC. Abnormal responses to orthostatic testing in children and adolescents with recurrent unexplained syncope.Am Heart J 1991;122:748–754.

    PubMed  Google Scholar 

  27. Almquist A, Goldenberg IF, Milstein S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope.N Engl J Med 1989;320:346–351.

    PubMed  Google Scholar 

  28. Gupta BN, Thames ND. Behavior of left ventricular mechanoreceptors with myelinated and nonmyelinated afferent vagal fibers in cats.Circ Res 1983;52:291–301.

    PubMed  Google Scholar 

  29. Thoren P. Role of cardiac vagal C-fibers in cardiovascular control.Rev Physiol Biochem Pharmacol 1979;86:1–94.

    PubMed  Google Scholar 

  30. Abboud FM, Aylward PE, Floras JS, Gupta BN. Sensitization of aortic and cardiac baroreceptors by arginine vasopressine in mammals.J Physiol 1986;377:251–265.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Laboratory, First Department of Medicine, Helsinki University Central Hospital, 00290, Helsinki, Finland

    Jyrki M. Lilleberg & Markku S. Nieminen

  2. Orion Research Center, Orion-Farmos Pharmaceuticals, Espoo, Finland

    Stig Sundberg & Taru Leikola-Pelho

Authors
  1. Jyrki M. Lilleberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stig Sundberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taru Leikola-Pelho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markku S. Nieminen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lilleberg, J.M., Sundberg, S., Leikola-Pelho, T. et al. Hemodynamic effects of the novel cardiotonic drug simendan: Echocardiographic assessment in healthy volunteers. Cardiovasc Drug Ther 8, 263–269 (1994). https://doi.org/10.1007/BF00877335

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877335

Key Words

Search

Navigation